Invesco DB Commodity Index Tracking Fund vs Halozyme Therapeutics Inc. Common Stock — how do they compare? Invesco DB Commodity Index Tracking Fund trades at $32.96 (market cap $1.92B), while Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 6.6× Invesco DB Commodity Index Tracking Fund's market cap, and Halozyme Therapeutics Inc. Common Stock is more actively traded (2,179,278 versus 1,375,556). Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Commodity Index Tracking Fund for 60 Days and Halozyme Therapeutics Inc. Common Stock for 1 Days on average.
| DBC | HALO | |
|---|---|---|
Market Cap | $1.92B | $12.58B |
Volume | 1,375,556 | 2,179,278 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $33.68 | $115.22 |
52-Week Low | $22.07 | $61.63 |
Typical Hold Time | 60 Days | 1 Days |
Enterprise Value | — | $14.49B |
Signals from Pluang's Aura AI — not financial advice
DBC trades at $32.91, up 1.23% with a bullish technical signal from moving averages. The company reported $82.59M revenue and $22.38M net income for 2024, showing improved profitability with a 27.1% margin. Strong cash flow from operations of $431.54M supports a healthy balance sheet with minimal debt and $1.28B shareholder equity. Recent news highlights commodity ETF strategies amid dollar weakness.
The outlook appears positive with technical momentum and fundamental improvement, though revenue volatility remains a concern. Investment opportunity lies in the debt-free balance sheet and cash generation, while risks include inconsistent revenue trends and commodity market exposure.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.
Read more on DBC →Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →